SCHEMBL6261925

SCHEMBL6261925

CC(C)(C)OC(=O)CNC(=O)c1ccc2c(c1)C(=O)C(=O)c1ccccc1-2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 7/20 1.00
CTSL P07711 2/20 0.67
PTPN13 Q12923 2/20 0.67
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
ATM Q13315 1/20 0.56
ALDH1A1 P00352 3/20 0.53
MEN1 O00255 1/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50
PKM P14618 1/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 1/20 0.50
HSD17B10 Q99714 1/20 0.50
S100A4 P26447 1/20 0.48
TERT O14746 2/20 0.47
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
LCK P06239 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6260964 0.97 PTPRC (1.00) PTPRCCTSLPTPN13NPC1RAB9A
SCHEMBL30571451 0.83 PTPRC (0.74) PTPRCCTSLPTPN13NPC1RAB9A
SCHEMBL26567399 0.83 PTPRC (0.74) PTPRCCTSLPTPN13NPC1RAB9A
SCHEMBL15855077 0.81 PTPRC (0.69) PTPRCCTSLPTPN13NPC1RAB9A
SCHEMBL2601917 0.81 PTPRC (0.68) PTPRCCTSLPTPN13NPC1RAB9A
SCHEMBL6262671 0.81 PTPRC (1.00) PTPRCCTSLPTPN13NPC1RAB9A
SCHEMBL8197262 0.81 PTPRC (0.71) PTPRCCTSLPTPN13NPC1RAB9A
SCHEMBL30572132 0.79 PTPRC (0.69) PTPRCCTSLPTPN13NPC1RAB9A
SCHEMBL8201092 0.79 PTPRC (0.65) PTPRCCTSLPTPN13NPC1RAB9A
SCHEMBL31725067 0.79 PTPRC (0.65) PTPRCCTSLPTPN13RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242363-B1 CD45 INHIBITORS ASTRAZENECA AB (SE) 2005-11-02 EP disclosed
US-20030207812-A1 Cd45 inhibitors ASTRAZENECA AB (SE) 2003-11-06 US disclosed
EP-1242363-A2 CD45 INHIBITORS AstraZeneca AB (SE) 2002-09-25 EP disclosed
WO-2001046125-A2 CD45 INHIBITORS ASTRAZENECA AB (SE) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207812-A1 Cd45 inhibitors CD74, CD2, PTPRC PTPRC 3/4885CTSL 2041/4885PTPN13 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.